Peptide receptor radionuclide therapy (PRRT) using [ 111 In-DTPA 0 ]octreotide (where
DTPA is diethylenetriaminepentaacetic acid) is feasible because, besides γ-radiation, 111 In …

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status
and effects of peptide receptor radionuclide therapy | European Journal of Nuclear Medicine …

OBJECTIVES Barrett's esophagus (BE) is a premalignant condition of the esophagus. It is a
consequence of mucosal injury from chronic gastroesophageal reflux in which bile acids are …

Tumor-induced angiogenesis can be targeted by RGD (Arg-Gly-Asp) peptides, which bind
to α v β 3 -receptors upregulated on angiogenic endothelial cells. RGD-containing peptides …

Background The continuous exposure of esophageal epithelium to refluxate may induce
ectopic expression of bile-responsive genes and contribute to the development of Barrett's …

The aim of this study was to develop and investigate a radiopeptide for the treatment of cancers
which overexpress cell surface somatostatin receptors. The new radiopharmaceutical is …

Receptor-targeted scintigraphy and radionuclide therapy with radiolabeled somatostatin
analogs are successfully applied for somatostatin receptor-positive tumors. The synergistic …

Peptide receptor scintigraphy with [ 111 In‐DTPA 0 ]octreotide (a stabilized radiolabeled
somatostatin (SS) analogue, OctreoScan®) is widely used for the visualization and staging of …

Somatostatin analogs promising for peptide receptor scintigraphy (PRS) and peptide receptor
radionuclide therapy (PRRT) are D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol) (Tyr 3 -…

Cisplatin is a potent DNA-damaging agent that has demonstrated anticancer activities
against several tumors. However, manifestation of cellular resistance is a major obstacle in …